Loading...
Loading...
IFRX| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 145.0K |
| Gross Profit | -145.0K |
| Operating Expense | 9,856.2K |
| Operating I/L | -9,856.2K |
| Other Income/Expense | 1,654.0K |
| Interest Income | 1,087.0K |
| Pretax | -8,202.1K |
| Income Tax Expense | 5.1K |
| Net Income/Loss | -8,202.1K |
InflaRx N.V. is a clinical-stage biopharmaceutical company specializing in the discovery and development of inhibitors using C5a technology. The company's lead product candidate, vilobelimab, is a first-in-class anti-C5a monoclonal antibody undergoing clinical trials for the treatment of various inflammatory diseases, including hidradenitis suppurativa, anti-neutrophil cytoplasm antibody associated vasculitis, pyoderma gangraenosum, and PD-1/PD-L1 inhibitor resistant/refractory cutaneous squamous cell carcinoma. In addition, InflaRx N.V. is developing INF904, an oral small molecule drug candidate, and IFX002 for chronic inflammation and autoimmune diseases. The company has co-development and clinical trial collaboration agreements with other biotechnology and pharmaceutical companies.
